ADM, which was first described in African-Americans, is seen also in Chinese subjects. These patients have significant residual C-peptide secretory capacity and should not be misdiagnosed and treated as patients with type 1 diabetes with life-long insulin therapy.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2000) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: